Chardan Capital analyst Gbola Amusa reiterated a Buy rating on RegenXBio (NASDAQ:RGNX) on Wednesday, setting a price target of $100, which is approximately 102.63% above the present share price of $49.35.
Amusa expects RegenXBio to post earnings per share (EPS) of $0.24 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in RegenXBio, with an average price target of $63.6.
The analysts price targets range from a high of $100 to a low of $31.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $98.91 million and a net profit of $13.95 million. The company's market cap is $1.68 billion.
According to TipRanks.com, Chardan Capital analyst Gbola Amusa is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 36.0% and a 55.13% success rate.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.